Who are we?

ChiraTecnics was founded in 2009 by Prof. Anthony Burke as a spin-out from the University of Évora, with the aim to manufacture and commercialise ligands, building blocks and catalysts for chiral synthesis.

Whilst the company still offers this portfolio to clients, it now mainly focuses on custom synthesis programmes to support medicinal chemistry and drug discovery projects for pharmaceutical and biotech companies. It is led by a strong international team and has access to all vital equipment to implement our projects.


 

News

 

June 2019

Chiratecnics took part in a EIT Health SLIM work-shop on business skills at the University of DELFT. 

Dec 2018

We are pleased to announce that we are sponsors of the International Symposium on Synthesis and Catalysis 2019 (ISySyCat2019) and will also be taking part in this exciting event.

https://isysycat2019.eventos.chemistry.pt/

 

 

 
 

 

Did you Know?

 

The CRO Market for API and other chemicals is buzzing at the moment.

Revenues in 2010 were $11.43 billion and it is estimated to reach $20.09 billion in 2020. Pharma is outsourcing more and more business to competent CROs.

  

Our mission is to provide

 

 

  • ChiraTecnics is a privately owned CRO with lab installations in the Alentejo Science and Technology Park (PCTA–Evora). We provide contract research services and high-added- value chemicals to the pharmaceutical and other industries. The company is already active in the market. We offer cutting edge chemical technologies, with extensive knowhow and experience, to rapidly respond to our customer’s needs applying the highest standards at the most affordable price. We also have access to an affordable highly qualified work- force. We pride ourselves on our openness, confidentiality and constant communication which is important for our customers and establishing mutual trust. We see our business as a fine art where we work with passion, creativity and flexibility to reliably meet the customers’ needs and expectations.